← All trials
NCT06672237
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2024
- Primary completion
- Jul 31, 2027
- Completion date
- Aug 31, 2028
- First posted
- Nov 4, 2024
- Last posted
- Nov 4, 2024
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Intellia TherapeuticsLead sponsor
- RegeneronCollaborator
Drugs studied
Indications studied
- Amyloidosis
- Metabolic Diseases
- Metabolism, Inborn Errors
- Nervous System Diseases
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Polyneuropathies
- Amyloid Neuropathies
- Neurodegenerative Diseases
- Heredodegenerative Disorders, Nervous System
- Amyloidosis, Familial
- Amyloid Neuropathies, Familial
- Genetic Diseases, Inborn
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.